PBAC's latest decision on Benralizumab: Recommended with restriction (2020). Considered for Treatment of uncontrolled severe eosinophilic asthma. New presentation (pre-filled pen/auto-injector form) as a treatment option.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2018
Submissions
3
2018 → 2020
Eligible population
Patients with uncontrolled severe eosinophilic asthma (same population as the pre-filled syringe form already listed on PBS)
Therapy area
Respiratory
Line of therapy
Not applicable
Evidence base
Single-arm
Primary endpoint
Surrogate
Pivotal trial size
180 patients
Key trials
AMES Clinical Study Report
Comparator
benralizumab pre-filled syringe (Fasenra PFS)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as the submission compared two presentations of the same drug with equi-effective doses and equal pricing.
Submission history
Mar 2018: Recommended with restriction · Restricted
Mar 2018: Noted · Restricted
Mar 2020: Recommended with restriction · Restricted